Ad
related to: genmab pharmaceuticals- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Careers
Search results
Results From The WOW.Com Content Network
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. [7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan.
Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for ...
They also said the results of the clinical trial would be submitted for presentation at an upcoming medical congress and discussed with regulatory authorities. "Demonstrating a survival benefit ...
About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms ...
Tisotumab vedotin was developed by Genmab in Utrecht, the Netherlands, and Copenhagen, Denmark, with the code name TF-011-MMAE. [5] In September 2021, tisotumab vedotin was granted accelerated approval by United States Food and Drug Administration for the use of recurrent or metastatic cervical cancer with disease progression on or after ...
Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. [9] Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma.
Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. [10] The company was acquired by Bristol Myers Squibb in 2009 for $2.4 billion, which included $300 million in debt, making the payment to Medarex $2.1 billion. [11] [12]
Ofatumumab was jointly developed by Danish biotech Genmab and GlaxoSmithKline GSK plc who entered into an agreement to co-develop and commercialize ofatumumab in 2006. [27] It was approved as Arzerra for the treatment of chronic lymphocytic leukemia in the United States in October 2009.
Ad
related to: genmab pharmaceuticals